Global Critical Care Therapeutics Market 2017-2021

  • ID: 4042770
  • Report
  • Region: Global
  • 101 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abeona Therapeutics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • Kamada
  • Novo Nordisk
  • Rockwell Medical
  • MORE
About Critical Care Therapeutics

Critical care or intensive care is the close monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents, complicated surgeries, sepsis, and severe breathing problems. It usually takes place in an ICU or trauma center. Plasma is the fluid portion of the blood, in which all the blood cells are suspended. It makes up about 55% of the total volume of the blood. The other components such as red blood cell (RBC), white blood cell (WBC), and platelets together comprise the remaining 45% of the blood. Plasma is mainly made up of water, which accounts for about 91% of the total volume.

The analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global critical care therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of critical care therapeutics was considered.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Critical Care Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors:
- CSL Behring
- Grifols
- Kedrion Biopharma
- Octapharma
- Shire

Other prominent vendors:
- Abeona Therapeutics
- ADMA Biologics
- Albumedix
- Armetheon
- Asklepios BioPharmaceutical
- Aspen Pharma
- Baxter
- Bayer HealthCare
- Bio Products Laboratory
- BioDelivery Sciences
- Biogen Idec
- BioMarin
- Biotest Pharmaceuticals
- Bristol-Myers Squibb
- Catalyst Biosciences
- China Biologic Products
- Cosmo Pharmaceuticals
- Kamada
- King Pharmaceuticals
- Medxbio
- Merck
- Mitsubishi Tanabe Pharma
- Novo Nordisk
- Novozymes
- Portola Pharmaceuticals
- ProMetic Life Sciences
- rEVO Biologics
- Rockwell Medical
- Sanquin
- Shanghai RAAS
- Teva Pharmaceutical
- The Medicines Company
- Thermo Fisher Scientific
- Tianjin SinoBiotech & Beijing Bio-Fortune
- Ventria Bioscience

Market drivers
- Growing preference for marketed products over alternative treatment options.
- For a full, detailed list, view the full report

Market challenges
- Existence of plasma fractionation supply and demand gap.
- For a full, detailed list, view the full report

Market trends
- Increased development of recombinant products for critical care use.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeona Therapeutics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • Kamada
  • Novo Nordisk
  • Rockwell Medical
  • MORE
Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction
  • Key market highlights
  • The role of plasma therapeutics in critical care industry
  • Introduction to plasma therapeutics
  • Introduction to anticoagulants
Part 05: Global critical care therapeutics: Market landscape
  • Market overview
  • Five forces analysis
Part 06: Market segmentation by drug class
  • Global albumin market
  • Global prothrombin complex concentrates market
  • Global antithrombin concentrates market
  • Global factor XIII concentrates market
  • Global fibrinogen concentrates market
Part 07: Market segmentation by application
  • DVT
  • Pulmonary embolism (PE)
  • Acute coronary syndrome
  • Atrial fibrillation
  • Hemodialysis
  • Coronary angioplasty
  • Surgeries
Part 08: Geographical segmentation
  • Critical care therapeutics market in Americas
  • Critical care therapeutics market in EMEA
  • Critical care therapeutics market in APAC
Part 09: Market drivers
  • High demand for albumin in China
  • Increasing surgical procedures
  • Growing preference for marketed products over alternative treatment options
  • Impact of drivers
Part 10: Market challenges
  • Existence of plasma fractionation supply and demand gap
  • Spread of pathogenic contaminants
  • High regulations of plasma products
Part 11: Impact of drivers and challenges

Part 12: Market trends
  • Increased development of recombinant products for critical care use
  • Establishment of plasma fractionation facilities in emerging economies by global players
  • Strategic initiatives of vendors fueling the market growth
Part 13: Vendor landscape
  • Competitive scenario
  • Other prominent vendors
Part 14: Key vendor analysis
  • CSL Behring
  • Grifols
  • Kedrion Biopharma
  • Octapharma
  • Shire
Part 15: Appendix
  • List of abbreviations
Part 16: About the Author
0

List of Exhibits
Exhibit 01: Composition of blood
Exhibit 02: Composition of plasma
Exhibit 03: Process of procurement and manufacturing of plasma therapeutics
Exhibit 04: Regulatory policies of plasma therapeutics life cycle
Exhibit 05: Process of blood coagulation
Exhibit 06: Mechanism of blood coagulation
Exhibit 07: Market snapshot of global critical care therapeutic market
Exhibit 08: Overview of global critical care therapeutic market 2016-2021
Exhibit 09: Global critical care therapeutic market snapshot: Developed and emerging market 2016-2021
Exhibit 10: Global critical care therapeutics market 2016-2021 ($ millions)
Exhibit 11: Opportunity analysis in global critical care therapeutics market
Exhibit 12: Five forces analysis
Exhibit 13: Market segmentation of global critical care therapeutics by drug class
Exhibit 14: Overview of global albumin market
Exhibit 15: Overview of global prothrombin complex concentrates market
Exhibit 16: Overview of antithrombin concentrates market
Exhibit 17: Overview of global factor XIII concentrates market
Exhibit 18: Overview of global fibrinogen concentrates market
Exhibit 19: Global critical care therapeutics market: Segmentation by geography 2016-2021
Exhibit 20: Global critical care therapeutics market segmentation by region: Market growth life cycle analysis 2016
Exhibit 21: Overview of critical care therapeutics market in Americas
Exhibit 22: Critical care therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 23: Opportunity analysis of critical care therapeutics market in Americas
Exhibit 24: Pest analysis of critical care therapeutics market in Americas
Exhibit 25: Overview of critical care therapeutics market in EMEA
Exhibit 26: Critical care therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 27: Opportunity analysis of critical care therapeutics market in EMEA
Exhibit 28: Pest analysis of critical care therapeutics market in EMEA
Exhibit 29: Overview of critical care therapeutics market in APAC
Exhibit 30: Critical care therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 31: Opportunity analysis of critical care therapeutics market in APAC
Exhibit 32: Pest analysis of critical care therapeutics market in APAC
Exhibit 33: Impact of drivers and challenges on global critical care therapeutics market
Exhibit 34: Impact of drivers
Exhibit 35: Demand and supply gap: Plasma-derived products (million liters/year)
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Impact of trends on global critical care therapeutics market
Exhibit 38: Overview of critical care therapeutics: M&A and licensing
Partnerships 2005-2012
Exhibit 39: Competitive structure analysis of global critical care therapeutics market 2016
Exhibit 40: Competitive analysis of global critical care therapeutics market
Exhibit 41: Market penetration of various plasma products manufacturers worldwide 2016
Exhibit 42: CSL Behring: Key highlights
Exhibit 43: CSL Behring: Strength assessment
Exhibit 44: CSL Behring: Strategy assessment
Exhibit 45: CSL Behring: Opportunity assessment
Exhibit 46: Grifols: Key highlights
Exhibit 47: Grifols: Strength assessment
Exhibit 48: Grifols: Strategy assessment
Exhibit 49: Grifols: Opportunity assessment
Exhibit 50: Grifols: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
Exhibit 51: Kedrion Biopharma: Key highlights
Exhibit 52: Kedrion Biopharma: Strength assessment
Exhibit 53: Kedrion Biopharma: Strategy assessment
Exhibit 54: Kedrion Biopharma: Opportunity assessment
Exhibit 55: Octapharma: Key highlights
Exhibit 56: Octapharma: Strength assessment
Exhibit 57: Octapharma: Strategy assessment
Exhibit 58: Octapharma: Opportunity assessment
Exhibit 59: Shire: Key highlights
Exhibit 60: Shire: Strength assessment
Exhibit 61: Shire: Strategy assessment
Exhibit 62: Shire: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abeona Therapeutics
  • Bayer HealthCare
  • Bristol-Myers Squibb
  • Kamada
  • Novo Nordisk
  • Rockwell Medical
  • MORE
New Report Released: – Global Critical Care Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global critical care therapeutics market: CSL Behring, Grifols, Kedrion Biopharma, Octapharma, and Shire.

Other Prominent Vendors in the market are: Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, Aspen Pharma, Baxter, Bayer HealthCare, Bio Products Laboratory, BioDelivery Sciences, Biogen Idec, BioMarin, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products, Cosmo Pharmaceuticals, Kamada, King Pharmaceuticals, Medxbio, Merck, Mitsubishi Tanabe Pharma, Novo Nordisk, Novozymes, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS, Teva Pharmaceutical, The Medicines Company, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, and Ventria Bioscience.

Commenting on the report, an analyst from the research team said: “One trend in market is establishment of plasma fractionation facilities in emerging economies by global players. Plasma fractionation in developed countries is proving very costly, so there has been a growing focus of vendors to tap the emerging economies such as the Middle East, Africa, China, and India. These geographies become a favorite due to the easy availability of skilled personnel, raw materials, cheap labor and land, a larger volume of available plasma due to large population base, and supportive government regulations. However, currently the presence of plasma fractionation facilities is very much limited to China within emerging countries, but in future, the incentives listed above should be driving the vendors to establish more facilities in these regions. For instance, in 2010, Celestial Biologicals, an associate company of Intas Biopharmaceuticals, in collaboration with GE Healthcare started a plasma fractionation facility in India. Going forward, to benefit from the unmet demand in the emerging markets and the incentives of opening such facilities in the region, would drive global players to open number of such facilities in the region.”

According to the report, one driver in market is increasing surgical procedures. The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT, thereby driving the market growth. Surgeries often result in long periods of immobility, thus increasing the chances of developing DVT due to reduced blood flow. It is reported that over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT. For instance, according to the CDC 2015 report, around 719,000 knee replacement surgeries and 332,000 hip replacement surgeries are performed in the US every year.

Further, the report states that one challenge in market is high regulations of plasma products. Manufacturers of critical care therapeutics need to follow rigorous and distinct sets of regulatory guidelines like the adherence to current good manufacturing practices (cGMP) during the donation and processing of the plasma products. These guidelines are applied both for the collection of plasma from donors and during the fractionation of plasma-derived products along with the manufacture and production of the final product. Various regulatory bodies like the WHO; European Commission Directorate-General for Health and Consumers (DG SANCO), EMA, EDQM, and NCAs in the EU; HHS, US FDA, and the CDC, in the US; and Anvisa and COFEPRIS in ROW regulate these processes. Also, the approval process for plasma products is very long. For instance, in China, the plasma products have to go through 10 different stages, which takes a minimum of 22-28 months to receive approval for commercialization in the market by the CFDA. Since the plasma collection and manufacturing units are required to follow these guidelines, which requires high cost and efficiency, many of the new players are unable to enter the market, thus hindering the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • CSL Behring
  • Grifols
  • Kedrion Biopharma
  • Octapharma
  • Shire
  • Abeona Therapeutics
  • ADMA Biologics
  • Albumedix
  • Armetheon
  • Asklepios BioPharmaceutical
  • Aspen Pharma
  • Baxter
  • Bayer HealthCare
  • Bio Products Laboratory
  • BioDelivery Sciences
  • Biogen Idec
  • BioMarin
  • Biotest Pharmaceuticals
  • Bristol-Myers Squibb
  • Catalyst Biosciences
  • China Biologic Products
  • Cosmo Pharmaceuticals
  • Kamada
  • King Pharmaceuticals
  • Medxbio
  • Merck
  • Mitsubishi Tanabe Pharma
  • Novo Nordisk
  • Novozymes
  • Portola Pharmaceuticals
  • ProMetic Life Sciences
  • rEVO Biologics
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS
  • Teva Pharmaceutical
  • The Medicines Company
  • Thermo Fisher Scientific
  • Tianjin SinoBiotech & Beijing Bio-Fortune
  • Ventria Bioscience
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll